Summit Therapeutics SMMT Stock
Summit Therapeutics Price Chart
Summit Therapeutics SMMT Financial and Trading Overview
| Summit Therapeutics stock price | 13.59 USD |
| Previous Close | 13.44 USD |
| Open | 13.44 USD |
| Bid | 12.19 USD x 200 |
| Ask | 14.16 USD x 200 |
| Day's Range | 13.01 - 13.59 USD |
| 52 Week Range | 12.25 - 30.98 USD |
| Volume | 4M USD |
| Avg. Volume | 5.05M USD |
| Market Cap | 10.39B USD |
| Beta (5Y Monthly) | -1.264 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.11 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.35 USD |
SMMT Valuation Measures
| Enterprise Value | 9.72B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.86474 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 18.494318 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -11.109 |
Trading Information
Summit Therapeutics Stock Price History
| Beta (5Y Monthly) | -1.264 |
| 52-Week Change | -55.59% |
| S&P500 52-Week Change | 18.32% |
| 52 Week High | 30.98 USD |
| 52 Week Low | 12.25 USD |
| 50-Day Moving Average | 14.77 USD |
| 200-Day Moving Average | 17.05 USD |
SMMT Share Statistics
| Avg. Volume (3 month) | 5.05M USD |
| Avg. Daily Volume (10-Days) | 4.32M USD |
| Shares Outstanding | 797.75M |
| Float | 152.29M |
| Short Ratio | 7.58 |
| % Held by Insiders | 80.89% |
| % Held by Institutions | 15.52% |
| Shares Short | 37.33M |
| Short % of Float | 24.57% |
| Short % of Shares Outstanding | 4.70% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -101.61% |
| Return on Equity (ttm) | -192.50% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -874670016 USD |
| Net Income Avi to Common (ttm) | -856089024 USD |
| Diluted EPS (ttm) | -1.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 690.68M USD |
| Total Cash Per Share (mrq) | 0.87 USD |
| Total Debt (mrq) | 20.38M USD |
| Total Debt/Equity (mrq) | 3.24 USD |
| Current Ratio (mrq) | 6.958 |
| Book Value Per Share (mrq) | 0.704 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -458432992 USD |
| Levered Free Cash Flow (ttm) | -139678496 USD |
Profile of Summit Therapeutics
| Country | United States |
| State | FL |
| City | Miami |
| Address | 601 Brickell Key Drive |
| ZIP | 33131 |
| Phone | 305 203 2034 |
| Website | https://www.smmttx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 265 |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Q&A For Summit Therapeutics Stock
What is a current SMMT stock price?
Summit Therapeutics SMMT stock price today per share is 13.59 USD.
How to purchase Summit Therapeutics stock?
You can buy SMMT shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Summit Therapeutics?
The stock symbol or ticker of Summit Therapeutics is SMMT.
Which industry does the Summit Therapeutics company belong to?
The Summit Therapeutics industry is Biotechnology.
How many shares does Summit Therapeutics have in circulation?
The max supply of Summit Therapeutics shares is 797.75M.
What is Summit Therapeutics Price to Earnings Ratio (PE Ratio)?
Summit Therapeutics PE Ratio is now.
What was Summit Therapeutics earnings per share over the trailing 12 months (TTM)?
Summit Therapeutics EPS is -1.11 USD over the trailing 12 months.
Which sector does the Summit Therapeutics company belong to?
The Summit Therapeutics sector is Healthcare.
Summit Therapeutics SMMT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26462.57 USD — |
-0.46
|
5.35B USD — | 26393.65 USD — | 26739 USD — | — - | 5.35B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2298.56 USD — |
-0.33
|
— — | 2292.51 USD — | 2320.36 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6631.04 USD — |
+0.8
|
— — | 6600.35 USD — | 6699.6 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1266.3 USD — |
+0.2
|
— — | 1260.71 USD — | 1278.44 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32647.21 USD — |
-0.46
|
— — | 32563.29 USD — | 32989.36 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}
